Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Poster session 05

1251P - Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial

Date

14 Sep 2024

Session

Poster session 05

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Emanuela Olmetto

Citation

Annals of Oncology (2024) 35 (suppl_2): S794-S801. 10.1016/annonc/annonc1601

Authors

E. Olmetto1, C. Mattioli1, S. Caini2, M. Del Riccio3, P. Garlatti1, G. Finocchiaro4, P. Borghetti5, G. Metro6, S. Pilotto7, F. Grossi8, G. Farina9, F.A. Meriggi10, A. Sbrana11, E. Roca12, A. Delmonte13, A. Russo14, M. Macerelli15, M. Perna16, A. Bruni17, V. Scotti1

Author affiliations

  • 1 Radiation Oncology Unit, AOUC - Azienda Ospedaliero-Universitaria Careggi, 50134 - Firenze/IT
  • 2 Cancer Risk Factors And Life-style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), 50134 - Florence/IT
  • 3 Department Of Health Sciences, University of Florence, 50134 - Florence/IT
  • 4 Medical Oncology And Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 - Rozzano/IT
  • 5 Radiation Oncology Department, ASST Spedali Civili and Brescia University, 25123 - Brescia/IT
  • 6 Medical Oncology Department, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT
  • 7 Section Of Innovation Biomedicine - Oncology Area, Department Of Engineering For Innovation Medicine (dimi), University of Verona and University and Hospital Trust (AOUI) of Verona, 37134 - Verona/IT
  • 8 Unit Of Medical Oncology, Department Of Medicine And Surgery, University of Insubria, ASST dei Sette Laghi, 22100 - Varese/IT
  • 9 Department Of Oncology, ASST Fatebenefratelli Sacco, 20121 - Milan/IT
  • 10 Uo Di Oncologia Medica, Casa di Cura Poliambulanza, 25124 - Brescia/IT
  • 11 Service Of Pneumo-oncology, AOU Pisana, 56124 - Pisa/IT
  • 12 Thoracic Oncology, Lung Unit, P. Pederzoli Hospital, Peschiera Del Garda (VR)/IT
  • 13 Medical Oncology Dept., IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., 47014 - Meldola/IT
  • 14 Department Of Onco-hematology, Papardo Hospital, 98158 - Messina/IT
  • 15 Department Of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale, 33100 - Udine/IT
  • 16 Oncology Unit, Santa Maria Annunziata Hospital, 50012 - Bagno a Ripoli/IT
  • 17 Oncology And Hematology - Radiotherapy Unit, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 1251P

Background

Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).

Methods

NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).

Results

Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P

Patients characteristics

Cohort A patients (%) 96 Cohort B patients (%) 94
Sex MF 62 (64.5%)34 (35.5%) 66 (70%)28 (30%)
Smoke YesNo 85 (88%)9 (12%) 85 (90%)9 (10%)
Age years MedianRange 68 y44-83 66 y42-84
Histology AdenocarcinomaSquamocellularOthers 54 (56%)39 (41%)3 (3%) 49 (52%)39 (41%)6 (7%)
PD-L1 expression 01-49≥ 50Not tested 12 (12.5%)41 (43%)30 (31%)13 (13.5%) 11 (12%)15 (16%)9 (10%)59 (62%)
Stage disease IIIAIIIBIIIC 35 (36.5%)48 (50%)13 (13.5%) 39 (41%)44 (47%)11 (12%)
ECOG PS 012 59 (61.5%)35 (37.5%)1 (1%) 60 (64%)34 (36%)0

Conclusions

Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.

Clinical trial identification

ESR-19-20410.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.